Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of pancreatic cancer

Background: Chimeric antigen receptor (CAR) T cell therapies are approved for the treatment of different hematological malignancies. In solid tumors, however, this approach has failed so far. A major limitation of CAR T cells is their ineffective infiltration into solid tumors. A prerequisite for an efficient migration and tumor homing of transferred T cells is the expression of matching chemokine receptors to the chemokines secreted by the tumor tissue. In this study, we genetically engineered tumor-specific T cells with the C-X-C chemokine receptor 6 (CXCR6) to enhance T cell trafficking and to improve adoptive tumor immunotherapy.